RC Capital exits after Medtronic acquires SPR Therapeutics
RC Capital exited its investment in SPR Therapeutics following Medtronic’s acquisition of the pain-management device maker.
The deal marked the sixth liquidity event for RC Capital’s Fund VI.
SPR Therapeutics expanded commercialization of its SPR Peripheral Nerve Stimulation System, a minimally invasive platform positioned as a non-opioid pain treatment.
The company reported 291 issued and pending patents, supported by more than 130 peer-reviewed publications on its SPRINT platform.
MDT•
